They further reveal that DNGR-1-mediated cross-presentation favors immune visibility of cancer clones bearing sequence mutations in proteins of the actin cytoskeleton, which are surprisingly common even in patients with low overall mutational burden (Figures S7A and S7B). This evidence concerns the gene CLEC9A and cancer.